Dx M&A Market Remains Stagnant in H1 2024

Macroeconomic uncertainty, confusion surrounding the diagnostic regulatory landscape, and the continuing post-COVID-19 pandemic hangover have all contributed to a stagnant, quiet period for mergers and acquisitions in the in vitro diagnostics space in the first half of 2024.

Download full PDF Article

Resources

A Shifting Market Environment and Strategies Fueling Innovation in Prostate Cancer Treatment

Blockbuster drug patent expiration, advances in enabling technology, and the emergence of personalized medicine for prostate cancer treatment create a landscape worth examining.

Download
Resources

Outcome Capital Life Science Market Pulse, March 2025

Outcome Capital Life Science Market Pulse March 2025 Click to view our LifeSciences Pulse Newsletter

Download

Contact Us for More Information

Would you like to learn more about working with Outcome Capital or discuss your specific needs?

Contact Us

  • Boston

    20 Custom House St, Suite 1200, Boston, MA 02110
    (617) 431-2278

© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC

Business Continuity Plan | Privacy Policy | Regulation Best Interest

Built by Metropolis